尊龙Z6官方网站

2023年4月27日
，尊龙Z6官方网站医药（港交所代码：02256）颁发
，公司自主研发且已获中美双沉突破性疗法认定的新一代CSF-1R抑造剂Pimicotinib（ABSK021）的两项沉大创新药物最新临床进展将在2023 ASCO Meeting 上颁布。 

2项钻研成就的提要具体内容为：  

Title: First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. 

First Author: Gerald Falchook, Sarah Cannon Research Institute at HealthONE

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 

Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 

Abstract #3100

Poster Bd #298 

Title: Efficacy and safety profile of pimicotinib (ABSK021) in tenosynovial giant cell tumor (TGCT): Phase 1b update. 

First Author: Hairong Xu, Ji Shui Tan Hospital, Peking University

Session Title: Sarcoma

Track: Sarcoma 

Abstract #11559 

Poster Bd #493